Recently, a published study showed that TNFRSF9 agonist combined with PD-L1 could effectively activate and amplify tumor-specific cytotoxic T cells, enhancing tumor control and killing (Geuijen et al., 2021). This evidence concerns the gene CD274 and neoplasm.